Clinical manifestations of AB‐amyloidosis: effects of biocompatibility and flux

Schiffl, Helmut; Fischer, Rainald; Lang, Susanne M.; Mangel, E.

doi:10.1093/ndt/15.6.840

Cited by 43 publications

(42 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…But most of the patients with CTS were treated with non-biocompatible membranes. Thus, the biocompatibility of dialysis membranes might play a role in the formation of DRA, which is in accordance with previous findings [2,15]. β2M levels were lower when biocompatible membranes were used [16].…”

Section: Discussionsupporting

confidence: 92%

“…In our study, the concentration of β2M was up to 30 times higher than in healthy subjects. Patients with CTS revealed a significantly higher concentration of β2M, which increased the probability for CTS confirming previous findings [3,15,17]. The lower residual renal function in CTS might have contributed to this.…”

Section: Discussionsupporting

confidence: 88%

“…In a Japanese cohort, patients with longer dialysis time showed higher rates of DRA and CTS independent of HF or LF [14]. Patients treated with HF had significantly lower concentrations of β2M than patients with LF [15]. In the present study, however, β2M was lower in LF, which was possibly related to the significantly lower residual renal function and a longer dialysis time in the HF group.…”

Section: Discussioncontrasting

confidence: 48%

See 2 more Smart Citations

Advanced Glycation End Products and β2-Microglobulin as Predictors of Carpal Tunnel Syndrome in Hemodialysis Patients

et al. 2012

View full text Add to dashboard Cite

Background/Aims: Carpal tunnel syndrome (CTS) is a common clinical presentation of dialysis-related amyloidosis. It was determined whether β₂-microglobulin (β2M) and advanced glycation end products in serum are predictors of CTS in dialysis patients. Methods: A total of 385 hemodialysis patients were screened for CTS. β2M in serum was determined by a competitive enzyme-linked immunoassay, CML by a competitive enzyme-linked immunosorbent assay and total pentosidine by reverse-phase high-performance liquid chromatography. Results: 127 patients (33%) were treated with biocompatible membranes, 174 (45%) with high-flux dialysis. 122 patients (31.7%) had clinical signs of CTS. Significant predictors of CTS were: age, female gender, serum β2M, total protein, dialysis with non-biocompatible high-flux dialysis compared to non-biocompatible low-flux dialysis, Kt/V and serum concentration of CML (OR 2.47 for the 3rd vs. 1st quartile, 95% CI 1.229–4.961, p = 0.011). Conclusion: The prevalence of CTS as a possible manifestation of dialysis-related amyloidosis is still high. Serum concentration of CML may be a predictor of CTS besides β2M and malnutrition.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 88%

Section: Discussioncontrasting

confidence: 48%

See 1 more Smart Citation

Advanced Glycation End Products and β2-Microglobulin as Predictors of Carpal Tunnel Syndrome in Hemodialysis Patients

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Moreover, the use of high-flux membranes was associated with a higher prevalence of CTS in the multivariate logistic regression analysis. These data are in contrast to other reports demonstrating lower β 2 -microglobulin levels in high-flux HD compared to low-flux HD of similar HD vintage and a lower prevalence of CTS in these patients [3,4]. …”

contrasting

confidence: 99%

Carpal Tunnel Syndrome in Patients on Intermittent Hemodialyis

Schiffl¹

2012

Blood Purif

Self Cite

View full text Add to dashboard Cite

“…It was reported that treatment with a high-flux dialyzer and a low-contaminant dialysis fluid yielded a lower β 2 m level and inhibited the onset of bone cysts compared with conventional HD [14,15,16]. Gejyo et al [4] reported an increase in number of bone cysts in a group given HD alone, but no additional formation of bone cysts in a group treated with Lixelle for 2 years.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of β2-Microglobulin Adsorption Column in Treating Dialysis-Related Amyloidosis: A Multicenter Study

Kuragano

Inoue

Shin³

et al. 2011

Blood Purif

View full text Add to dashboard Cite

Background/Aims: The aim of this study was to determine whether treatment with β₂-microglobulin adsorption column (Lixelle) affects bone cysts and clinical symptoms in patients with dialysis-related amyloidosis (DRA). Methods: Radiographic changes in the number and area of bone cysts of the wrist and the hip joint were compared between 39 hemodialysis (HD) patients treated with Lixelle (Lixelle group) and 28 HD patients treated with conventional therapy as retrospective control (HD group). Clinical symptoms of DRA were also evaluated. Results: In the Lixelle group, the number of bone cysts and the cystic area in wrist joints were significantly decreased, although the changes in these parameters in hip joints were not significant. In the HD group, the corresponding parameters in the hip joints even significantly increased. Clinical symptoms notably improved after Lixelle treatment. Conclusion: Treatment with Lixelle reduces the radiolucency of bone cysts in the wrist joints, and improves clinical symptoms associated with DRA.

show abstract

Clinical manifestations of AB‐amyloidosis: effects of biocompatibility and flux

Cited by 43 publications

References 23 publications

Advanced Glycation End Products and β<sub>2</sub>-Microglobulin as Predictors of Carpal Tunnel Syndrome in Hemodialysis Patients

Advanced Glycation End Products and β<sub>2</sub>-Microglobulin as Predictors of Carpal Tunnel Syndrome in Hemodialysis Patients

Carpal Tunnel Syndrome in Patients on Intermittent Hemodialyis

Effectiveness of β<sub>2</sub>-Microglobulin Adsorption Column in Treating Dialysis-Related Amyloidosis: A Multicenter Study

Contact Info

Product

Resources

About